Ipca Laboratories Limited

NSE IPCALAB.NS

Ipca Laboratories Limited Operating Cash Flow for the year ending March 31, 2024: USD 113.25 M

Ipca Laboratories Limited Operating Cash Flow is USD 113.25 M for the year ending March 31, 2024, a 15.51% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Ipca Laboratories Limited Operating Cash Flow for the year ending March 31, 2023 was USD 98.04 M, a -13.04% change year over year.
  • Ipca Laboratories Limited Operating Cash Flow for the year ending March 31, 2022 was USD 112.74 M, a -24.27% change year over year.
  • Ipca Laboratories Limited Operating Cash Flow for the year ending March 31, 2021 was USD 148.88 M, a 98.83% change year over year.
  • Ipca Laboratories Limited Operating Cash Flow for the year ending March 31, 2020 was USD 74.88 M, a 5.70% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
Loading...
NSE: IPCALAB.NS

Ipca Laboratories Limited

CEO Mr. Pranay Premchand Godha
IPO Date Jan. 1, 1996
Location India
Headquarters 125, Kandivli Industrial Estate
Employees 17,335
Sector Health Care
Industries
Description

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Similar companies

AJANTPHARM.NS

Ajanta Pharma Limited

USD 32.53

1.58%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 37.58

0.68%

APLLTD.NS

Alembic Pharmaceuticals Limited

USD 11.66

0.86%

ALKEM.NS

Alkem Laboratories Limited

USD 60.83

0.86%

DIVISLAB.NS

Divi's Laboratories Limited

USD 69.21

4.65%

StockViz Staff

January 15, 2025

Any question? Send us an email